Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edwards Lifesciences Corporation (NYSE: EW) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a structural heart medical device manufacturer. These filings, sourced from the SEC’s EDGAR system, include current reports on material events, earnings announcements, capital markets activity and other items relevant to shareholders and analysts.
Edwards Lifesciences uses Form 8‑K to report developments such as quarterly financial results, financial guidance updates, leadership transitions, accelerated share repurchase agreements and legal or regulatory matters. Recent 8‑K filings, for example, describe third‑quarter financial results, a planned chief financial officer transition, an accelerated share repurchase agreement and legal proceedings related to the Federal Trade Commission’s successful motion to block the proposed acquisition of JenaValve Technology.
In addition to current reports, investors typically review Edwards’ annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which provide detailed information on its structural heart portfolio, risk factors, research and development spending, and segment performance across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies and surgical heart valves. Proxy statements on Schedule 14A and beneficial ownership or insider trading reports on Forms 3, 4 and 5 offer further insight into governance and executive equity activity.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language, highlight important changes from prior periods and help readers interpret complex sections. Real‑time updates ensure that new Edwards Lifesciences filings appear promptly, while AI‑generated overviews of 10‑K, 10‑Q and Form 4 documents can assist users in quickly understanding the implications of lengthy disclosures and insider transactions without replacing their own review of the original filings.
Edwards Lifesciences Corp executive Donald E. Bobo Jr., Corporate Vice President of Strategy and Corporate Development, reported an open-market sale of 24,000 shares of common stock on February 25, 2026 at a weighted average price of $83.8365 per share. After this sale, he directly owned 21,266.2532 shares. Indirect holdings were updated to 38,900.5862 shares through a 401(k) plan and 121,756 shares held by a trust, reflecting a correction of 13,396 shares that were previously reported as directly held. The sale price reflects multiple trades executed between $83.66 and $83.96.
EW reported an insider sale notice for Common stock showing 24,000 shares listed to be sold on
The excerpt also lists prior sales by BOBO JR FAMILY TRUST on
Edwards Lifesciences outlines its 2025 business, emphasizing leadership in structural heart therapies. Transcatheter Aortic Valve Replacement (TAVR) remains the core franchise, representing 74% of 2025 net sales, while Transcatheter Mitral and Tricuspid Therapies contributed 9% and Surgical Structural Heart valves 17%.
The company reports an aggregate market value of common stock held by non‑affiliates of $45,899,189,298 as of June 30, 2025, with 580.8 million shares outstanding as of January 31, 2026. Research and development spending rose about 2% and reached roughly 18% of 2025 sales, reflecting heavy investment in next‑generation TAVR, TMTT and surgical platforms.
Edwards generated 58% of net sales in the United States and 42% internationally, operates in about 100 countries, and employed roughly 16,000 people as of December 31, 2025. The filing details extensive risk factors, including innovation and clinical trial execution, manufacturing quality, competition from Medtronic and Abbott, reimbursement pressure, global regulatory change, cybersecurity, AI governance, and tax and compliance exposure.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, reported a tax-related share disposition. On
Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026. The shares were disposed of at a reported price of $79.78 per share, and he now directly holds about 9,089.4805 shares.
Ullem Scott B. reported disposition transactions in a Form 4 filing for EW. The filing lists transactions totaling 199 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 39,699 shares.
Lippis Daniel J. reported multiple insider transaction types in a Form 4 filing for EW. The filing lists transactions totaling 13,276 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 34,366 shares.
Edwards Lifesciences CEO Bernard J. Zovighian reported several share transactions. On February 12, 2026, he exercised employee stock options covering 25,350 shares of common stock at an exercise price of
On February 13, 2026, he reported bona fide gifts of 2,920 shares of common stock at
Edwards Lifesciences Corp insider Bernard J Zovighian filed a Rule 144 notice to sell 22,430 shares of common stock, with an aggregate market value of $1,719,742.00. The proposed sale is through Charles Schwab & Co., Inc. on the NYSE around 02/12/2026.
The notice states that 580,300,000 shares of common stock were outstanding; this is a baseline figure, not the amount being sold. It also lists prior sales over the past three months of 21,487 and 3,863 Edwards Lifesciences shares, with gross proceeds of $1,831,006.00 and $322,367.00, respectively.
Edwards Lifesciences reported strong growth for the quarter and year ended Dec. 31, 2025, while GAAP earnings were pressured by large one‑time charges. Q4 net sales rose 13.3% to $1.57 billion, led by Transcatheter Aortic Valve Replacement (TAVR) sales of $1.16 billion, up 12.0%, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $156 million, which grew more than 40%.
Q4 diluted EPS from continuing operations was $0.11, while adjusted EPS was $0.58, reflecting exclusions such as $208.6 million of certain litigation expenses and a $99.8 million loss on impairment in the quarter. Full‑year 2025 net sales increased 11.5% to $6.07 billion, with TAVR and TMTT both delivering double‑digit constant‑currency growth.
The company guided to 2026 constant‑currency sales growth of 8–10% and expects TMTT revenue of $740–$780 million, implying 35–45% growth. Edwards also targets 2026 adjusted EPS of $2.90–$3.05 and an adjusted operating margin at the high end of a 28–29% range, supported by a broad structural heart portfolio and multiple product and clinical trial catalysts.